Clinical Trial Update: Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing MAB-22 with Prolia (denosumab) for osteoporosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• MAB-22
• Prolia (denosumab)

Snippet

Sponsor: Xentria, Inc. | Conditions: Osteoporosis | Phase 3 | Status: WITHDRAWN